drugset / Trial / NCT04351126

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

NCT04351126

Phase 2 Completed 107 enrolled Ganin Fertility Center
RandomizedParallel-groupOpen-labelTreatment

Summary

lines of evidence that support nature of ovarian hyperstimulation syndrome (OHSS) as "defective mineralocorticoid response" are cited, our hypothesis is tested clinically in both prophylaxis against and treatment of OHSS.

Timeline

Start
2019-04-01
Primary completion
2020-02-25
Completion
2020-02-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fludrocortisone Other / unclassified 0.1 mg
Background Bromocriptine Small molecule 2.5 mg Other